Interaction between rs10830962 polymorphism in MTNR1B and lifestyle intervention on maternal and neonatal outcomes: secondary analyses of the DALI lifestyle randomized controlled trial
Por:
van Poppel, MNM, Corcoy, R, Hill, D, Simmons, D, Mendizabal, L, Zulueta, M, Simon, L, Desoye, G, Perez, JMA, Kautzky-Willer, A, Harreiter, J, Damm, P, Mathiesen, E, Jensen, DM, Andersen, LLT, Dunne, F, Lapolla, A, Dalfra, MG, Bertolotto, A, van Poppel, M, Jelsma, JGM, Snoek, FJ, Galjaard, S, Wender-Ozegowska, E, Zawiejska, A, Devlieger, R, DALI Core Investigator Grp
Publicada:
9 feb 2022
Ahead of Print:
1 dic 2021
Resumen:
Background Interactions between polymorphisms of the melatonin receptor 1B (MTNR1B) gene and lifestyle intervention for gestational diabetes have been described. Whether these are specific for physical activity or the healthy eating intervention is unknown. Objectives The aim was to assess the interaction between MTNR1B rs10830962 and rs10830963 polymorphisms and lifestyle interventions during pregnancy. Methods Women with a BMI (in kg/m(2)) of >= 29 (n = 436) received counseling on healthy eating (HE), physical activity (PA), or both. The control group received usual care. This secondary analysis had a factorial design with comparison of HE compared with no HE and PA compared with no PA. Maternal outcomes at 24-28 wk were gestational weight gain (GWG), maternal fasting glucose, insulin, insulin resistance (HOMA-IR), disposition index, and development of GDM. Neonatal outcomes were cord blood leptin and C-peptide and estimated neonatal fat percentage. The interaction between receiving either the HE or PA intervention and genotypes of both rs10830962 and rs10830963 was assessed using multilevel regression analysis. Results GDM risk was increased in women homozygous for the G allele of rs10830962 (OR: 2.60; 95% CI: 1.34, 5.06) or rs10830963 (OR: 2.83; 95% CI: 1.24, 6.47). Significant interactions between rs10830962 and interventions were found: in women homozygous for the G allele but not in the other genotypes, the PA intervention reduced maternal fasting insulin (beta: -0.16; 95% CI: -0.33, 0.02; P = 0.08) and HOMA-IR (beta: -0.17; 95% CI: -0.35, 0.01; P = 0.06), and reduced cord blood leptin (beta: -0.84; 95% CI: -1.42, -0.25; P = 0.01) and C-peptide (beta: -0.62; 95% CI: -1.07, -0.17; P = 0.01). In heterozygous women, the HE intervention had no effect, whereas in women homozygous for the C allele, HE intervention reduced GWG (beta: -1.6 kg; 95% CI: -2.4, -0.8 kg). No interactions were found. Conclusions In women homozygous for the risk allele of MTNR1B rs10830962, GDM risk was increased and PA intervention might be more beneficial than HE intervention for reducing maternal insulin resistance, cord blood C-peptide, and cord blood leptin.
Filiaciones:
van Poppel, MNM:
Karl Franzens Univ Graz, Inst Human Movement Sci Sport & Hlth, Graz, Austria
Corcoy, R:
Inst Recerca Hosp Santa Creu & St Pau, Barcelona, Spain
Inst Salud Carlos III, CIBER Bioengn Biomat & Nanotechnol, Madrid, Spain
Hill, D:
Rech Sante Lawson SA, Bronschhofen, Switzerland
Lawson Hlth Res Inst, London, ON, Canada
Simmons, D:
Western Sydney Univ, Campbelltown, NSW, Australia
Addenbrookes Hosp, Inst Metab Sci, Cambridge, England
Mendizabal, L:
Patia Europe, San Sebastian, Spain
Zulueta, M:
Patia Europe, San Sebastian, Spain
Simon, L:
Med Univ Graz, Dept Obstet & Gynecol, Graz, Austria
Desoye, G:
Med Univ Graz, Dept Obstet & Gynecol, Graz, Austria
van Poppel, M:
Karl Franzens Univ Graz, Inst Human Movement Sci Sport & Hlth, Graz, Austria
|